TNYA TNYA
Company Profile ↓Company Overview
TNYA (TNYA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +13.23% |
| 6 Months: | -14.24% |
| 3 Months: | +4.07% |
| 1 Month: | -14.71% |
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 62.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 225.00K |
| Operating Income | - | -8.87M | -10.45M | -13.11M | -15.24M | -18.30M | -31.15M | -28.62M | -31.30M | -33.72M | -35.10M | -30.92M | -33.76M | -30.82M | -26.71M | -27.54M | -24.08M | -20.94M | -20.07M |
| Net Income | -9.05M | -8.73M | -10.29M | -13.10M | -15.21M | -18.26M | -31.06M | -28.40M | -30.70M | -31.74M | -33.27M | -29.14M | -32.23M | -29.43M | -25.63M | -26.86M | -23.28M | -20.27M | -19.27M |
| Diluted EPS | - | - | - | - | - | -0.68 | -0.75 | -0.69 | -0.74 | -0.43 | -0.45 | -0.39 | -0.40 | -0.34 | -0.30 | -0.24 | -0.14 | -0.12 | -0.09 |
| R&D Expense | - | 6.96M | 8.48M | 9.59M | 10.91M | 12.94M | 24.16M | 20.88M | 23.76M | 25.61M | 26.48M | 23.09M | 25.05M | 22.65M | 20.35M | 21.08M | 17.37M | 15.36M | 14.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -38.91M | -72.81M | -125.62M | -131.19M | -115.95M | -93.33M |
| Net Income | -38.40M | -72.72M | -123.67M | -124.08M | -111.13M | -90.60M |
| Diluted EPS | - | -4.10 | -2.76 | -1.68 | -1.31 | -0.59 |
| R&D Expense | 31.10M | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 148.16M | 314.19M | 278.94M | 170.51M | 119.94M | 146.92M |
| Total Equity | -43.74M | -81.31M | 278.53M | 243.38M | 139.42M | 92.85M | 123.27M |
| Cash & Equivalents | - | 128.53M | 38.13M | 95.27M | 45.68M | 4.32M | 100.55M |
| Total Liabilities | - | 8.72M | 35.66M | 35.57M | 31.09M | 27.09M | 23.66M |
| Current Liabilities | - | 5.04M | 21.77M | 24.25M | 22.73M | 15.97M | 15.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -35.45M | -60.81M | -104.42M | -102.07M | -90.50M | -68.26M |
| Investing Cash Flow | -7.01M | -238.56M | 83.65M | 48.72M | 1.13M | 56.08M |
| Financing Cash Flow | 147.27M | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Capital Expenditure | -9.76M | -25.12M | -20.63M | -1.24M | -1.02M | -618.00K |
| Free Cash Flow | -45.21M | -85.93M | -125.05M | -103.31M | -91.53M | -68.88M |
| Share Buybacks | 1.00K | 13.00K | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 47.2% | -26.1% | -50.8% | -89.0% | -119.7% | -73.5% |
| ROCE % | -27.2% | -24.9% | -49.3% | -88.8% | -111.5% | -71.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNYA
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discussions on Pivotal Tria…
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the …
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the u…
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational ExpertiseSOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company wi…
Exploring 3 High Growth Tech Stocks in US Market
The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks inv…
Exploring High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has seen a decline of 4.1%, yet it remains up by 21% over the past year with earnings projected to grow by 18% annually in the coming years. In this context, identifying high growth tech stocks…
TNYA — Frequently Asked Questions
What is the current share price of TNYA?
As of 2026-08-05 17:25 PDT, TNYA trades at $0.78 on NASDAQ/NYSE. Its 52-week range is $0.55 to $2.10.
What is the P/E ratio of TNYA?
TNYA trades at a trailing price-to-earnings (P/E) ratio of -1.32.
What is the return on equity (ROE) of TNYA?
TNYA has a return on equity (ROE) of -73.50%. Its return on capital employed (ROCE) is -70.98%.
Is TNYA a good stock to buy?
This page provides a data-driven analysis of TNYA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.